Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025)
Monopar Therapeutics (MNPR) posted Cash from Financing Activities of -$384680.0 for Q4 2025, down 100.42% sequentially from $92.4 million in Q3 2025, and down 100.69% YoY from $56.1 million in Q4 2024.
Powered by 
Analysis
Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Monopar Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at -$384680.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 100.69% year-over-year to -$384680.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $91.6 million (up 54.45% YoY) and the FY2025 annual result came in at $91.6 million, up 54.45% from the prior year.
- Cash from Financing Activities retreated to -$384680.0 in Q4 2025 per MNPR's latest filing, from $92.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $92.4 million in Q3 2025 and troughed at -$384680.0 in Q4 2025.
- A 5-year average of $8.2 million and a median of -$8845.5 in 2021 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 558897.68% in 2025, down 3094.32% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$7772.0 in 2021, then soared by 1885.09% to $138737.0 in 2022, then jumped by 141.14% to $334548.0 in 2023, then jumped by 16679.9% to $56.1 million in 2024, then slumped by 100.69% to -$384680.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$384680.0, $92.4 million, and -$316845.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Monopar Therapeutics | 1.01 Bn | 954.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -384,680.00 |
| Sep 30, 2025 | 92.39 Mn |
| Jun 30, 2025 | -316,845.00 |
| Mar 31, 2025 | -115,682.00 |
| Dec 31, 2024 | 56.14 Mn |
| Sep 30, 2024 | -16,534.00 |
| Jun 30, 2024 | -9,919.00 |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 334,548.00 |
| Sep 30, 2023 | 246,703.00 |
| Jun 30, 2023 | 641,178.00 |
| Mar 31, 2023 | 804,798.00 |
| Dec 31, 2022 | 138,737.00 |
| Sep 30, 2022 | -23,738.00 |
| Jun 30, 2022 | -65,460.00 |
| Mar 31, 2022 | -16,666.00 |
| Dec 31, 2021 | -7,772.00 |
| Sep 30, 2021 | -9,978.00 |
| Jun 30, 2021 | -24,003.00 |
| Mar 31, 2021 | 10.92 Mn |